Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907 is registered in ClinicalTrials.gov with Myrtelle Inc. as lead sponsor.

NCT NCT04833907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04833907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Lead sponsor
Myrtelle Inc.
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
April 1, 2021
Completion date
August 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

canavan disease